Report Library
All ReportsWet Age-Related Macular Degeneration (Wet AMD) KOL Interview – US #2
September 29, 2022
A US-based KOL speaks on the current market trends and how cost, durability, and efficacy play a key role in prescribing decisions. The KOL also talks about newer therapies that might overthrow current market leaders, and the future of newer biologics in the market.
If you are a KOL Insight Subscriber, please access the interview from our KOL Insight portal (Subscribers only).
Biomedtracker's KOL Insight transcripts are available through subscription only. For more information on obtaining a KOL Insight subscription, please email Biomedtracker or call Biomedtracker Client Services at (888) 670-8900.
For our disclosures, please read the Biomedtracker Research Standards.Indications Covered: | Wet Age-Related Macular Degeneration (Wet AMD) (Ophthalmology) |
Additional Resources: